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Abstract
Major depressive disorder (MDD) is frequently diagnosed in military personnel returning from deployment. Literature
suggests that MDD is associated with a pro-inflammatory state. To the best of our knowledge, no prospective, longitudinal
studies on the association between development of depressive symptomatology and cytokine production by peripheral
blood leukocytes have been published. The aim of this study was to investigate whether the presence of depressive
symptomatology six months after military deployment is associated with the capacity to produce cytokines, as assessed
before and after deployment. 1023 military personnel were included before deployment. Depressive symptoms and LPS-
and T-cell mitogen-induced production of 16 cytokines and chemokines in whole blood cultures were measured before (T0),
1 (T1), and 6 (T2) months after return from deployment. Exploratory structural equation modeling (ESEM) was used for data
reduction into cytokine patterns. Multiple group latent growth modeling was used to investigate differences in the
longitudinal course of cytokine production between individuals with (n=68) and without (n=665) depressive symptoms at
T2. Individuals with depressive symptoms after deployment showed higher T-cell cytokine production before deployment.
Moreover, pre-deployment T-cell cytokine production significantly predicted the presence of depressive symptomatology 6
months after return. There was an increase in T-cell cytokine production over time, but this increase was significantly smaller
in individuals developing depressive symptoms. T-cell chemokine and LPS-induced innate cytokine production decreased
over time and were not associated with depressive symptoms. These results indicate that increased T-cell mitogen-induced
cytokine production before deployment may be a vulnerability factor for development of depressive symptomatology in
response to deployment to a combat-zone. In addition, deployment to a combat-zone affects the capacity of T-cells and
monocytes to produce cytokines and chemokines until at least 6 months after return.
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Introduction
Mental health disorders frequently diagnosed in military
personnel after deployment include major depressive disorder
(MDD). Prevalence estimates for MDD range from 7.3% to 15.9%
in US infantry soldiers 12 months after return from deployment to
Iraq [1]. A number of studies have investigated the capacity of
peripheral leukocytes of individuals with MDD or depressive
symptoms to produce cytokines after in vitro stimulation.
Increased [2–7], unaltered [8–12] and decreased [2,13,14]
mitogen-induced pro-inflammatory cytokine production by leuko-
cytes from individuals with MDD or depressive symptoms
compared to non-depressed controls have been reported. Howev-
er, in the majority of these studies only a small number of
predominantly innate pro-inflammatory cytokines has been
investigated. In addition, all of these studies have been performed
within a cross-sectional design, with a different ‘time since onset’ of
the depressive symptoms. Therefore, it is as yet unknown whether
a causal relation exists between the development of MDD and the
capacity to produce cytokines.
The potential involvement of inflammatory mediators in
depression is underscored by the observation that individuals with
lifetime MDD have epigenetic changes in methylation of
inflammation-associated genes [15]. In addition, meta-analyses
investigating the association between MDD and circulating levels
of C-reactive protein (CRP), innate pro-inflammatory cytokines
IL-6, TNF-a, IL-1, and the IL-1 receptor antagonist showed that
these inflammatory markers are increased in MDD [16,17]. These
effects were present within both clinical and community samples,
and in studies using clinical interviews and studies using self-report
measures [16]. Furthermore, higher amounts of circulating IL-2
soluble receptors (s-IL2-r) [18–20] have been observed in
individuals with MDD or depressive symptomatology.
In the current study our aim was to determine whether the level
of mitogen-induced cytokine production before and/or after
deployment was associated with the presence of a high level of
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deployment. We used a prospective, longitudinal design, in which
data were collected before, as well as 1 and 6 months after
deployment to a combat-zone. We investigated the production of a
broad range of innate and T-cell cytokines, including pro- and
anti-inflammatory cytokines, as well as chemokines. There is
functional overlap between cytokines, and chance capitalization
for type-I errors will occur when testing 16 longitudinal models.
Therefore, we performed data reduction by using exploratory
structural equation modeling (ESEM), which is a recently
developed statistical method in which exploratory factor analysis
is performed within a structural equation modeling setting [21].
Subsequently, differences in the longitudinal course of cytokine
production between individuals with and without depressive
symptomatology 6 months after deployment were investigated
using multiple group latent growth modeling (LGM) [22]. In
addition, logistic regression analysis was performed to test the
predictive value of cytokine production for the presence of
depressive symptomatology after deployment.
Materials and Methods
Ethics Statement
The study was approved by the Institutional Review Board of
the University Medical Center Utrecht, the Netherlands. Written
informed consent was obtained after participants got a written and
verbal description of the study.
Participants
Military personnel of the Dutch Armed Forces assigned to a 4-
month deployment to Afghanistan were included in this study.
Duties during deployment included combat patrols, clearing or
searching homes and buildings, participation in de-mining
operations, and transportation across enemy territory. They were
exposed to typical war-zone stressors such as exposure to enemy
fire, armed combat, and seeing seriously injured and dead fellow
soldiers and civilians (including women and children).
Participants were assessed 1 to 2 months prior to deployment
(T0) and approximately 1 (T1) and 6 months (T2) after their
return. At each assessment, participants filled out several ‘paper-
and-pencil’ questionnaires. In addition, a heparinized blood
sample was drawn between 8.00 and 11.30 a.m. Heparinized
blood was kept at room temperature. Data were collected between
April 2005 and September 2009.
We included 1023 participants before deployment. Twenty-
eight participants (2.5%) were not available for follow-up (non-
deployed (n=26); deceased during deployment (n=2)). Of the
eligible 995 participants, 825 completed the assessment at T1
(82.9%) and 749 completed the assessment at T2 (75.3%).
Compared to eligible individuals who completed the T2
assessment, dropouts were younger during deployment (mean
(SD): dropouts: 26.03 (7.08); completers: 29.09 (9.24), t(976):
24.604, p,.001). Consequently they had been deployed less
often (mean (SD): dropouts: 0.55 (0.88); completers: 0.93 (1.23),
t(886): 24.03, p,.001) and were lower ranked (x
2
(3): 21.656,
p,.001). There were no significant differences in gender
distribution (x
2
(1): 1.738, p=.187) and educational level (x
2
(2):
5.922,p=.052). In addition, there were no differences in pre-
deployment questionnaire scores for depression (t(821): 0.385,
p=.701) and PTSD (t(682): 0.247, p=.805).
Depression scores at T2 were missing for 16 participants (2.1%).
The remaining 733 participants were divided into two groups
based on their level of depressive symptoms at T2. Participants
were assigned to the depressive symptoms group when their score
on the Symptom Checklist (SCL-90) depression subscale was $24
at T2 (n=68) [23]. This cut-off corresponds to the mean plus 2
standard deviations (95
th percentile) on the SCL-90 depression
subscale within a population of 840 Dutch military personnel
(mean (SD): 18.06 (3.15)). Participants scoring below the cut-off on
the SCL-90 depression subscale at T2 were assigned to the non-
depressed group (n=665).
Questionnaires
Level of depressive symptoms over the past week was assessed
with the Dutch version of the Symptom Checklist (SCL-90)
depression subscale [24]. This subscale consists of 16 items ranging
from 1 (not at all) to 5 (very much). The total depressive symptom
score is the sum score for all items (range 16–80). A higher score
indicates more depressive symptoms. The questionnaire has good
reliability and is frequently used within research and clinical
settings. The validity of the subscale as a screening instrument for
MDD has been shown in primary care patients [25], and in the
aftermath of stroke [26] and myocardial infarction [27].
Depression and PTSD are frequently co-morbid [28]. There-
fore, the level of posttraumatic stress disorder (PTSD) symptoms
over the past 4 weeks was assessed with the Dutch 22-item Self-
Report Inventory for PTSD (SRIP). The questionnaire consists of
three subscales representing the PTSD symptom clusters re-
experiencing, avoidance and hyper-arousal. The total PTSD score
is the sum score for all items (range: 22–88). The SRIP is well
validated and has good concurrent validity with other PTSD
measures such as the Clinician Administered PTSD Scale (CAPS)
and Mississippi scale for PTSD [29,30]. Exposure to deployment-
stressors was assessed with a 13-item checklist [31].
Collected demographics included age during deployment, sex,
body height, weight, smoking, alcohol use, and use of possibly
interfering medication (non-systemic glucocorticoids (nasal spray
or cre `me), antihistamines, cholesterol lowering medications and
antihypertensive medication). Body Mass Index (BMI) was
calculated by dividing body weight by the square of body height
(kg/m
2).
Cytokine production
CD2/CD28-induced T cell cytokine production. Whole
blood, diluted 1:10 with RPMI-1640 (Gibco, Grand Island, NY),
100 U/ml penicillin, 100 mg/ml streptomycin and 2 mML -
glutamine was stimulated with the T-cell mitogen anti-CD2/
CD28 monoclonal antibodies (CLB, Amsterdam, Netherlands,
final concentration anti-CD2.1/anti-CD2.2 0.33 mg/ml and anti-
CD28 1.33 mlg/ml) for 72 hours at 37u C/5% CO2 in 96-well
round-bottomed plates [32,33]. T cell mitogen-induced secretion
of interleukin (IL)-2, IL-4, IL-5, IL-6, IL-10, TNF-a, monocyte
chemoattractant protein (MCP)-1 (CCL2), interferon-gamma
induced protein (IP)-10 and RANTES (CCL5) were measured in
supernatants using multiplex cytokine assay as described before
[34–37]. IFN-c was analyzed by ELISA (CLB, Amsterdam, the
Netherlands).
Lipopolysaccharide-induced innate cytokine production.
Whole blood, diluted 1:10 with RPMI-1640 (Gibco, Grand Island,
NY), was stimulated with Lipopolysaccharide (LPS, Escherichia Coli
0127:B8, Sigma, final concentration 1 ng/ml) for 24 hours at 37u C/
5% CO2 in 96-well flat-bottomed plates to activate cytokine
production. Supernatants were analyzed by using multiplex assay
for the presence of IL-1a,I L - 1 b,I L - 6 ,I L - 8 ,I L - 1 0a n dT N F - a,a s
described previously [37].
FACS analysis. Leukocyte subsets in peripheral blood were
assessed using dual colour fluorescence analysis with a Becton
Dickinson Calibur flowcytometer. Whole blood was stained using
Cytokines, Depression and Military Deployment
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cyanate or phyco-erythrin to quantify CD14+ (monocytes), CD3+
(total T-cells), CD4+ (T-helper/inducer) and CD8+ (T-cytotoxic/
suppressor-effector) cells. Absolute numbers of cells were
calculated from a total leukocyte count.
Data analysis
Basic statistical analyses were conducted using SPSS 15.0.
Exploratory structural equation modeling (ESEM), multiple group
latent growth modeling and logistic regression analysis were
performed using Mplus 6.1 [38]. Immune parameters and
questionnaire scores were tested for normality and transformed
when necessary (see Table 1 for applied transformations). A
limited number of missing values in the immune parameters were
present due to technical and handling problems (cytokines: T0:
0.91%, T1: 1.46%, T2: 2.00%; cell subsets: T0: 1.68%, T1:
1.41%, T2: 2.93%). Outliers in the immune parameters were
removed if z-values were outside the range of 63.29 [39]
(cytokines: T0: 0.57%, T1: 0.80%, T2: 0.89%; cell subsets: T0:
1.17%, T1: 0.85%, T2: 0.45%).
Exploratory structural equation modelling. For data
reduction of the cytokines, exploratory structural equation
modeling (ESEM) was used [21]. Within this recently developed
statistical method, exploratory factor analysis (EFA) is performed
within a structural equation modeling (SEM) setting. Combining
EFA with SEM provides the opportunity to assess goodness-of-fit
indices and measurement invariance of the factor solution across
time or groups, which was previously not possibly within EFA.
ESEM is more appropriate to model complex biological data than
conventional confirmatory factor analysis (CFA): whereas CFA
only provides adequate model fit with simple structure (i.e. each
indicator loads on one pre-determined factor), in ESEM all
indicator loadings on all factors are estimated by default [21].
ESEM was performed, using data from T0 of all participants
with 1–5 specified factors, using maximum likelihood estimation.
To select the best fitting model the Aikake information criterion
(AIC [40]) and Bayesian information criterion (BIC [41]) of the
models were compared. The model with the smallest AIC and BIC
was chosen. Additionally, the comparative fit index (CFI), Tucker-
Lewis index (TLI), root mean square error of approximation
(RMSEA) and standardized root mean square residual (SRMR)
were used to test the goodness-of-fit of the models. Adequate fit
was defined as CFI.0.9, TLI.0.9, RMSEA,0.08, and
SRMR,0.08 [42].
Subsequently, it was investigated whether the chosen ESEM
model for T0 was stable (i.e. measurement invariant) across time.
For reliable estimation of differences in mean factor scores across
time, the presence of scalar and metric measurement invariance
(i.e. similar factor loadings and item means across time) is a
prerequisite [42,43]. For this purpose ESEM with target rotation
was performed, using data from T0–T2. Insignificant factor
loadings at T0 were estimated at 0 in the target model to simplify
the final model [21].
To deal with missing data, full information maximum likelihood
estimation (FIML) was used, which includes all available data in
the model. Thus, individuals with missing time points or missing
values within time points were retained in the analyses. This
provides more reliable estimates compared to other methods of
handling missing data, such as list-wise deletion or mean
imputation [44].
Multiple group latent growth modelling. Within latent
growth modeling, the average starting point (intercept) and
average change over time (slope) are estimated in longitudinal
data [22]. In multiple group latent growth modeling (LGM),
models are estimated simultaneously across groups. Using multiple
group LGM we investigated whether the intercept and slope of
questionnaire scores, cytokine production (factor scores) and cell
subsets differed between participants with and without a high level
of depressive symptoms at T2. A two-step model was used. First,
means of the intercepts and slopes were freely estimated across
groups. Then, a model was examined in which the intercept and
slope were constrained to be equal for both groups. Chi-square
difference testing (Dx
2) was used to formally test whether the more
constrained model fitted the data as well as the non-constrained
model: a significant Dx
2 indicates that the more constrained
model fits the data significantly worse [38]. When significant
group differences in intercept and slope were found, the
association between possibly confounding variables and the
intercept and/or slope of both groups was tested.
Logistic regression analysis. Logistic regression analysis
was performed to test the predictive value of cytokine factor scores
for the presence of depressive symptomatology. In the regression
analysis, pre-deployment SCL-90 depression score and BMI,
which differed between groups, were included to determine that
the observed association between cytokine factors scores and
depression were not confounded by these variables. To be able to
compare the odds ratios associated with the included variables,
variables were standardized (mean (SD): 0(1)).
Results
Participant characteristics
Participants were assessed 1 to 2 months before a 4-month
military deployment to Afghanistan (T0), and 1 (T1) and 6 (T2)
Table 1. CD2/CD28- and LPS- induced cytokine and
chemokine production before (T0), 1 (T1) and 6 (T2) months
after deployment.
T0 T1 T2
Mean SD N Mean SD N Mean SD N
CD2/
CD28
IL-2
a 1082.6 1369.1 995 1243.9 1591.0 819 1387.1 1654.1 743
IL-4
a 79.2 84.5 1002 115.2 129.4 814 125.2 135.0 742
IL-5
a 613.1 1008.1 983 642.4 1026.0 811 715.2 1088.4 736
IL-6
a 1229.5 1348.6 991 977.1 831.0 810 937.1 843.6 742
IL-10
b 432.7 356.8 999 543.3 454.4 817 589.1 440.7 744
TNF-a
a 560.8 475.7 1000 837.0 853.1 802 1209.3 1089.8 733
IFN-c
a 20593.2 23593.4 998 21117.9 21951.8 764 28376.0 34652.1 708
MCP-1
a 18308.0 14514.0 998 14577.4 10102.1 817 12728.2 8818.9 741
IP-10
b 5977.5 3485.5 994 7355.7 4539.4 818 9099.8 5977.1 744
RANTES
a 7142.0 6893.1 995 6298.5 4833.4 815 5069.5 4514.0 741
LPS
IL1-a
a 68.3 51.1 1002 60.1 47.0 793 57.0 41.4 721
IL1-b
b 314.4 227.4 996 260.6 179.0 802 241.1 156.6 730
IL-6
b 2951.7 1812.7 1008 2492.8 1988.3 806 2201.1 1286.4 712
IL-8
b 1955.9 1144.3 1006 2048.0 1087.3 805 2069.7 1076.8 725
IL-10
a 33.8 35.6 1006 28.8 25.5 805 31.0 28.7 733
TNF-a
a 851.5 677.9 1005 578.7 467.5 796 489.2 385.7 729
alog10-transformation applied;
b square root-transformation applied.
doi:10.1371/journal.pone.0029142.t001
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reported a high level of depressive symptoms at T2. The intensity
and frequency of depressive symptoms increased over time in the
group with depressive symptoms at T2, while the mean depressive
symptom score of the non-depressed group decreased slightly over
time. The group with a high level of depressive symptoms at T2
already had more depressive symptoms before deployment than
the non-depressed group (depressive symptoms group: intercept:
1.327(0.013), p,.001; slope: 0.010(0.001), p,.001. non-depressed
group: intercept: 1.241 (0.002), p,.001; slope: 20.001 (0.000),
p=.004; Dx
2
(3): 130.939, p,.001).
Individuals with depressive symptoms at T2 reported higher
levels of PTSD symptoms at T2 (t(726): 217.546, p,.001),
although the variance in SRIP total scores was considerable. In
addition, individuals with a high level of depressive symptoms at
T2 reported a larger number of deployment stressors, including a
larger number of combat experiences (Table 2). Furthermore,
BMI at T0 was higher in individuals who had depressive
symptoms at T2 (t(675): 22.203, p=.028).
Data reduction of cytokine parameters
We determined 10 CD2/CD28-induced and 6 LPS-induced
cytokines before (T0), 1 (T1) and 6 months (T2) after deployment.
Non-transformed values and applied transformations for the
CD2/CD28- and LPS-induced cytokine production are reported
in Table 1. We performed data reduction by exploratory structural
Table 2. Questionnaire scores and deployment, demographic and pre-deployment characteristics of the total sample, and the
sample divided based on depressive symptoms 6 months after return from deployment.
Total sample
(n=1023)
Depressive symptoms
6 months after
deployment (n=68)
No depressive
symptoms
6 months after
deployment (n=665) P
SCL-90 depression score T0
(range: 16–80)
18.06 (3.15) 22.15 (5.47) 17.55 (2.33) ,.001
SCL-90 depression score T1
(range: 16–80)
18.30 (3.83) 24.63 (5.87) 17.71 (3.10) ,.001
SCL-90 depression score T2
(range: 16–80)
18.34 (4.16) 29.12 (5.39) 17.24 (1.75) ,.001
SRIP (PTSD) total score T2
(range: 22–88)
27.79 (7.15) 40.44 (10.88) 26.54 (5.21) ,.001
Nr. Of deployment stressors (range: 0–13) 4.77 (2.55) 5.63 (2.40) 4.75 (2.55) .013
Age during deployment 28.44 (8.89) 29.54 (8.84) 28.98 (9.20) .629
Nr. Of previous deployments 0.83 (1.16) 1.08 (1.31) 0.92 (1.23) .268
Gender .729
Male 931 (91.0%) 61 (98.7%) 605 (91%)
Female 92 (9.0%) 7 (10.3%) 60 (9%)
Education .675
Low 371 (40.0%) 29 (44.6%) 242 (39.2%)
Middle 454 (48.9%) 28 (43.1%) 299 (48.5%)
High 103 (11.1%) 8 (12.3%) 76 (12.3%)
Rank during deployment .844
Soldier 400 (40.2%) 24 (35.3%) 246 (37.1%)
Corporal 206 (20.7%) 16 (23.5%) 134 (20.2%)
Non-commissioned officer 255 (25.7%) 20 (29.4%) 185 (27.9%)
Officer 133 (13.4%) 8 (11.8%) 98 (14.8%)
BMI T0 24.71 (2.78) 25.54 (3.41) 24.70 (2.74) .028
Smoking T0 (yes) 407 (44.5%) 28 (43.8%) 258 (42.2%) .814
Alcohol use T0 .786
None 93 (10.3%) 7 (11.3%) 63 (10.5%)
0–20 units/week 754 (83.9%) 50 (80.6%) 502 (83.5%)
.20 units/week 52 (5.8%) 5 (8.1%) 36 (6.0%)
Medication use T0 (yes) 56 (5.5%) 3 (4.4%) 42 (6.3%) .533
Season of assessment T0 .181
Spring 343 (33.5%) 27 (39.7%) 204 (30.7%)
Summer 102 (10.0%) 9 (13.2%) 67 (10.1%)
Autumn 308 (30.1%) 13 (19.1%) 202 (30.4%)
Winter 270 (26.4%) 19 (27.9%) 192 (28.9%)
doi:10.1371/journal.pone.0029142.t002
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Correlation matrices of the immune parameters revealed that IL-8
was only weakly correlated with the other variables (strongest
correlation -.13 with MCP1). IL-8 was therefore not included in
the factor analyses. We analyzed consecutive ESEM models with
1–5 factors respectively. According to the AIC and BIC measures,
the 5-factor model provided the best fit (Table S1). However,
within this model the estimated residual variance for CD2/CD28-
induced IL-4 was negative, and therefore this variable was
removed from the model [45]. We reran the 5-factor model
without CD2/CD28-induced IL-4 and obtained a better fit
compared to the 5-factor model including IL-4 (AIC=34271,
BIC=34704). Within this model the estimated factor loading for
LPS-induced IL-6 was larger than 1. This cytokine only loaded on
one factor, with small factor loadings from the other variables on
this factor (largest standardized loading:.044), and was removed
from the model as suggested [45]. We then analyzed a 4 factor
model without CD2/CD28-induced IL-4 and LPS-induced IL-6.
The model had good fit and lower AIC/BIC than the previous
model (CFI=.962, TLI=.908, RMSEA=.086, SRMR=.026,
AIC=27052, BIC=27406). The factor structure was similar at
T1 and T2 compared to T0 (i.e. model with scalar and metric
measurement invariance fitted the data better than the free model)
(model fit: CFI=.862, TLI=.835, RMSEA=.072, SRMR=
.074, AIC=63043, BIC=64015).
The first factor that emerged out of the ESEM including the
data from T0–T2 contained CD2/CD28-induced cytokines.
Given the evidence that CD2/CD28 is a strong activator of T-
cells [33], we refer to Factor 1 as T-cell cytokine production. Since
CD2 is also expressed on NK-cells, NK-cells may also contribute
to the production of the cytokines in this factor. The second factor
included all CD2/CD28-induced chemokines and CD2/CD28
induced IL-6 (referred to as T-cell-induced chemokine/IL-6
production). The third factor included all LPS-induced cytokines
(referred to as innate cytokine production). The fourth factor
contained CD2/CD28-induced IP-10 with lower loadings of
CD2/CD28-induced TNF-a and RANTES and LPS-induced IL-
10. This factor could not be interpreted in a functional way, and
therefore we chose not to include it in the subsequent analyses.
The final factor solution is depicted in Table 3. Most cytokines had
significant cross-loadings, underscoring the appropriateness of
using an ESEM model.
Longitudinal trajectory of mitogen-induced T-cell
cytokine production
We investigated whether the longitudinal course of T-cell
cytokine production (Factor 1) differed between the group with
high levels of depressive symptoms at T2 and the non-depressed
group. The multiple group latent growth model in which the
intercept and slope of both groups were constrained to be equal,
fitted the data less well (AIC=4975, BIC=5039) (Dx
2
(2)=8.784,
p=.012) than the model in which the intercept and slope were
freely estimated for both groups (CFI=.990, TLI=.971,
RMSEA=.101, SRMR=.020, AIC=4970, BIC=5043). Addi-
tional models constraining the intercept and slope separately
confirmed that both intercept and slope differed between the two
groups (intercept-model: Dx
2
(1): 7.449, p=.006; slope-model:
Dx
2
(1): 4.395, p=.036).
Before deployment, the group with depressive symptoms at T2
already had higher T-cell cytokine production than the non-
depressed group (depressive symptoms group: 0.296 (0.103),
p=.004; non-depressed group: 20.016 (0.036), p=.661). T-cell
cytokine production increased over time for both groups, but the
magnitude of the increase was significantly smaller in the
depressed group (depressive symptoms group: 0.018 (0.007),
p=.003; non-depressed group: 0.033 (0.003), p,.001)
(Figure 1A).
Since the group with depressive symptoms at T2 also had a
higher level of PTSD symptoms at T2, we investigated whether
this might have influenced the observed association between
depressive symptoms and T-cell cytokine production. PTSD
Table 3. Final exploratory structural equation _odelling (ESEM) factor solution.
Factor 1 Factor 2 Factor 3 Factor 4
T-cell
cytokines T-cell-induced chemokines/IL-6
Innate
cytokines
Residual
factor
CD2/CD28
IL-2 .815 2.048 .013 2.071
IL-5 .663 .044 2.036 .010
IL-6 .462 .488 .024 2.107
IL-10 .662 2.154 .000 .094
TNF-a .812 .142 .054 .206
IFN-c .867 .001 .022 2.068
MCP-1 2.019 .835 .137 2.014
IP-10 .491 .388 .000 .447
RANTES .455 .518 2.063 2.258
LPS
IL-1a 2.061 2.322 .837 .173
IL-1b .001 .001 .700 .001
IL-10 2.068 2.137 .507 .232
TNF-a 2.060 .054 .715 2.180
Indicator loadings ..3 are depicted in bold.
doi:10.1371/journal.pone.0029142.t003
Cytokines, Depression and Military Deployment
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e29142symptoms at T2 were not significantly associated with the
intercept and slope of T-cell cytokine production in both groups
(depressive symptoms group: intercept: 0.383 (0.871), p=.660;
slope: 0.027 (0.053), p=.610; non-depressed group: intercept:
20.469 (0.483), p=.0332; slope: 0.036(0.036), p=.316).
In addition, since the group with depressive symptoms reported
a higher number of deployment stressors, we investigated whether
the group difference in experienced deployment stressors might
explain the difference in change in cytokine production over time
between the groups. However, the number of reported deploy-
ment-stressors was not significantly associated with the slope of T-
cell cytokine production in both groups (depressive symptoms
group: 20.003 (0.003), p=.254; non-depressed group: 20.001
(0.001), p=.257). These findings indicate that the group difference
in the trajectory of cytokine production over time cannot be
attributed to differences in the number of experienced deployment
stressors.
We investigated whether the observed higher level of T-cell
cytokine production in the depressed group was associated with
group differences in the longitudinal course of total numbers of T-
cells (CD3+), cytotoxic/suppressor-effector T-cells (CD8+), and T-
helper cells (CD4+). The intercept and slope of the cell subsets did
not differ between groups for CD3+ T-cells (Dx
2
(2)=2.038,
p=.361), CD8+ cytotoxic/suppressor-effector T-cells (Dx
2
(2)=
4.189, p=.123), and CD4+ T-helper cells (Dx
2
(2)=2.088,
p=.352) (Figure 1CDE). In addition, the increased T-cell cytokine
production over time was not caused by an increase in the number
of T-cells or T-cell subsets over time. The number of CD8+
cytotoxic/suppressor-effector T-cells decreased over time within
both groups (depressive symptoms group: 20.001 (0.000),
p=.018; non depressed group: 0.000 (0.000), p=.002 (standard-
ized estimate: 20.162). The total number of T-cells (depressive
symptoms group: 20.007 (0.004), p=.115; non-depressed group:
20.002 (0.001), p=.132) and T-helper cells did not significantly
change over time (depressive symptoms group: 20.001 (0.003),
p=.819; non-depressed group: 0.000 (0.000), p=.899).
Longitudinal trajectory of mitogen-induced T-cell
chemokine/IL6 production
Next, we investigated whether the longitudinal course of T-cell-
induced chemokine/IL-6 production (Factor 2) differed between
the group with high levels of depressive symptoms at T2 and the
non-depressed group. T-cell chemokine production decreased over
time for both groups (depressive symptoms group: 20.027(0.008),
p=.001; non-depressed group: 20.028 (0.003), p,.001)
(Figure 1B). Comparison of the models with freely estimated
(AIC=4875, BIC=4948) and constrained intercepts and slopes
(CFI=1.000, TLI=.1.000, RMSEA=.000, SRMR=.022,
AIC=4872, BIC=4936) showed that the intercept and slope
did not significantly differ between the two groups (Dx
2
(2)=1.258,
p=.533).
Longitudinal trajectory of mitogen-induced innate
cytokine production
Innate cytokine production (Factor 3) decreased over time for
both groups (depressive symptoms group: 20.052 (0.010), p,.001;
non-depressed group: 20.051 (0.003), p,.001) (Figure 2A). The
model fit of the models with freely estimated intercepts and slopes
(AIC=5726, BIC=5749) was not significantly better than the
model fit of the model with constrained intercepts and slopes
(CFI=0.974, TLI=.0.961, RMSEA=.090, SRMR=.037,
AIC=5722, BIC=5787) (Dx
2
(2)=0.592, p=.745). Therefore
we concluded that there were no differences in intercept and slope
between groups.
The decrease in innate cytokine production over time was not
due to a decrease in total numbers of monocytes over time. In fact,
the total number of monocytes significantly increased over time
within both groups (depressive symptoms group: 0.002 (0.000),
p,.001; non-depressed group: 0.001 (0.000), p,.001) (Figure 2B).
There were no differences in the intercept and slope between
depressed and non-depressed individuals (fit unconstrained model:
AIC=6311, BIC=6240; fit constrained model: CFI=.992,
Figure 1. Longitudinal course of T-cell cytokine production and T-cell counts. Longitudinal course of CD2/CD28-induced Factor 1: T-cell
cytokine production (A); CD2/CD28-induced Factor 2: T-cell chemokine/IL-6 production (B) and CD3+ T-cell counts (C); CD8+ cytotoxic/suppressor-
effector T-cell counts (D) and CD4+ T helper-cell counts (E), as assessed before deployment (T0), 1 month (T1) and 6 months (T2) after return from
deployment. The course of the group with depressive symptoms at T2 (n=69) is depicted by the black circles (mean + SEM). The course of the group
without depressive symptoms at T2 (n=664) is depicted by the white rectangles (mean + SEM).
doi:10.1371/journal.pone.0029142.g001
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6250; Dx
2
(2)=2.980, p=.225).
Predictive value of T-cell cytokine production at T0 for
depressive symptomatology at T2
Multiple group LGM revealed that individuals with high levels
of depressive symptoms had higher T-cell cytokine production at
T0, compared to individuals who did not have depressive
symptoms at T2. The predictive value of T-cell cytokine
production at T0 for the presence of a high level of depressive
symptoms at T2 was investigated using logistic regression analysis.
We also included depressive symptoms and BMI at T0, to
ascertain that these pre-deployment group differences did not
confound our results. T-cell cytokine production at T0 signifi-
cantly and independently predicted the presence of depressive
symptomatology at T2 (estimate (SE): 0.615 (0.191), p=.001): with
each standard deviation increase in T-cell cytokine production at
T0 the odds for the presence of a high level of depressive
symptoms at T2 increased approximately 1.9-fold (Odds Ratio:
1.850). In addition, depressive symptoms at T0 also significantly
predicted the presence of a high level of depressive symptoms at
T2 (Odds ratio for 1 SD increase: 2.955; estimate (SE): 1.083
(0.141), p,.001). Pre-deployment BMI was not significantly
associated with the presence of depressive symptoms at T2 (Odds
ratio for 1 SD increase: 1.254; estimate (SE): 0.226 (0.141),
p=.103).
Discussion
This is the first prospective, longitudinal study in which
associations between the capacity of T-cells and monocytes to
produce cytokines and the development of depressive symptoms in
response to a period of severe stress have been investigated. We
aimed to investigate whether T-cell and monocyte cytokine
production represent vulnerability factors for the development of
a high level of depressive symptoms in response to a period of
severe stress.
To the best of our knowledge, the association between
depression and the capacity of monocytes and T-cells to produce
cytokines has only been investigated using cross-sectional designs.
Moreover, these cross-sectional studies predominantly determined
innate cytokines and investigated only a limited range of pro-
inflammatory cytokines. We used a unique design: within a large
cohort of participants, three assessments were performed,
spanning a time period from approximately 1 month before
deployment to a combat-zone, until approximately 6 months after
return. Moreover, we investigated the production of a broad range
of LPS- and CD2/CD28-induced pro- and anti-inflammatory
cytokines, and also included several chemokines in our analyses.
The majority of our participants appeared to be resilient and
reported no depressive symptoms six months after deployment.
However, 10% of the participants reported a high level of
depressive symptoms six months after deployment. We aimed to
investigate whether these participants with high levels of depressive
symptoms had different longitudinal trajectories in cytokine
production than the participants who did not become depressed.
For this purpose, we decided to use a dichotomous approach in
which participants were divided into groups with high and low
levels of depressive symptoms six months after deployment (i.e. a
score above or below cut-off on the SCL90 depression subscale).
Our results show that individuals with a high level of depressive
symptoms 6 months after return from deployment already had
higher T-cell mitogen-induced cytokine production before de-
ployment compared to individuals without depressive symptoms 6
months after return. Moreover, T-cell cytokine production before
deployment was a significant predictor of the presence of
depressive symptoms after deployment. Although the group with
depressive symptoms after deployment already had a larger mean
depression score before deployment, the observed predictive value
of the T-cell cytokines was independent of the severity of
depressive symptoms before deployment. Thus, our findings
indicate that high mitogen-induced T-cell cytokine production
before deployment is a pre-existing vulnerability factor for the
development of depressive symptoms in response to a period of
severe stress, in this case military deployment. In addition, the
observed high T-cell cytokine production was not caused by the
presence of posttraumatic stress symptoms in a subset of
participants with depressive symptoms: the depressive group did
report a higher level of posttraumatic stress symptoms 6 months
after deployment, but the T-cell cytokine production was
unrelated to the severity of these posttraumatic stress symptoms.
We did not observe differences in the number of T-cells (CD3+,
CD4+ and CD8+) before deployment between individuals with
and without depressive symptoms after deployment. Hence, the
observed higher T-cell cytokine production before deployment in
individuals with depressive symptoms after deployment is not
Figure 2. Longitudinal course of innate cytokine production and monocytes. Longitudinal course LPS-induced Factor 3: innate cytokine
production (A); and monocyte counts (B), as assessed before deployment (T0), 1 month (T1) and 6 months (T2) after return from deployment. The
course of the group with depressive symptoms at T2 (n=69) is depicted by the black circles (mean + SEM). The course of the group without
depressive symptoms at T2 (n=664) is depicted by the white rectangles (mean + SEM).
doi:10.1371/journal.pone.0029142.g002
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blood samples obtained from these individuals. Therefore, we
propose that the higher T-cell cytokine production in individuals
with depressive symptoms reflects a higher capacity of T-cells to
produce cytokines that may be related to an increased activation
status of these cells.
Higher circulating serum levels of soluble receptors for the T-
cell cytokine IL-2 (sIL-2r) have been observed previously in
individuals with MDD and depressive symptomatology compared
to non-depressed individuals [18–20]. In addition, in individuals
with cancer, treatment with high doses of the T cell cytokine IL-2
induces a cluster of mood and cognitive symptoms, overlapping
with MDD [46] and the depressive symptoms observed in our
study, in up to 60% of treated individuals, depending on the dose
and modality of treatment [47–49]. Interestingly, higher levels of
circulating T-cell cytokines in serum were found to be predictive
for the development of MDD in response to cytokine administra-
tion: higher levels of circulating sIL-2r, and of the anti-
inflammatory cytokine IL-10 [50] before the start of IFN-a
treatment were associated with increased risk for development of
MDD in response to the treatment. These previous findings
support our observation of the involvement of both pro- and anti-
inflammatory T-cell cytokines in the development of depressive
symptomatology.
Our data may also add to the theory that increased cytokine
production leads to increased signalling to brain structures
involved in the development of depressive symptomatology [48].
The pro-inflammatory cytokine IFN-c had the highest loading on
our T-cell cytokine factor, and therefore had the largest
contribution to the score of each participant on the T-cell cytokine
factor. Studies on inflammation-induced depressive-like behavior
in mice have shown that IFN-c may be a pivotal mediator in the
development of depressive-like behavior, since the development of
depressive-like behavior after immune activation by Bacille
Calmette-Guerin (BCG) was completely attenuated in IFN-c
receptor knock-out mice [51]. Indoleamine 2,3-dixoygenase (IDO)
is a likely intermediate in this relationship [for review see 47, 48,
52]. This tryptophan metabolising enzyme is upregulated by pro-
inflammatory cytokines like IFN-c and inhibition of IDO activity
as well as genetic ablation of IDO prevents development of
depressive-like behavior in response to BCG [53]. IDO-dependent
degradation of tryptophan leads to production of its metabolite
kynurenine, which is further metabolised to quinolinic acid and
kynurenic acid, an NMDA-receptor agonist and NMDA-receptor
antagonist respectively. Glutamergic dysfunction has been impli-
cated in the development of MDD. In addition, trypophan/
kynurenine and kynurenic acid/kynurenine ratios appear to be
distorted in individuals with cytokine-induced MDD as well as in
otherwise healthy individuals with MDD [48].
We observed pre-existing higher levels of T-cell cytokine
production in individuals who subsequently developed depressive
symptomatology after exposure to a period of severe stress, i.e.
military deployment, suggesting increased T-cell functioning prior
to the development of depressive symptoms. In apparent contrast
to our data, decreased mitogen-induced T-cell proliferation in
vitro and decreased virus-specific T-cell responses in vivo have
been observed in individuals who already had developed MDD
[54,55], indicating decreased T-cell function within these
individuals. Based on these previous studies, we speculate that
depressive symptomatology may decrease T-cell function over
time. In this respect it is of interest that IDO can inhibit T-cell
function [52]. It is possible that the observed higher capacity of T-
cells to produce cytokines in individuals vulnerable to development
of depressive symptoms eventually results in upregulation of IDO
by peripheral antigen presenting cells. Therefore, one could
suggest that in the long run, upregulation of IDO may contribute
to the downregulation of T-cell function in depressed individuals.
Exploratory structural equation _odelling, in which exploratory
factor analysis is performed within a structural equation _odelling
setting [21], was used for reduction of the cytokine data. This
advanced statistical method permitted us to reduce the complex
dataset into factor scores and to investigate the longitudinal
stability of our obtained factor solution. The raw data of T-cell-
produced cytokines and monocyte-induced cytokines support our
factor solution in which pro- and anti-inflammatory cytokines load
on the same factors: we did not observe differences in the direction
of the observed change over time between pro- and anti-
inflammatory cytokines.
The longitudinal design of our study also allowed us to
investigate the effect of military deployment on mitogen-induced
cytokine production within the whole sample. Military deployment
induced changes in mitogen-induced T-cell cytokine production,
T-cell-induced chemokine/IL6 production and innate cytokine
production. Interestingly, the direction of the observed change in
cytokine production upon stimulation differed between monocytes
and T-cells. Innate cytokine production decreased over time. In
contrast, the total number of monocytes increased over time for
both groups, indicating that the total capacity of a single monocyte
to produce cytokines upon stimulation decreased even more
strongly over time. The production of T-cell-induced chemokines
and IL-6 after stimulation also decreased over time, as well as the
number of cytotoxic/suppressor-effector T-cells (CD8+). In
contrast, the T-cell cytokine production in response to a mitogen
was increased after return from deployment. The observed
changes in cytokine production over time were not caused by
differences in season during the subsequent assessments influenced
our results.
Our group previously reported that mitogen-induced cytokine
production was not a stable trait, but differed over time in healthy
adolescents, depending on the season of assessment [35].
Nevertheless, after correcting our latent growth models for the
seasons in which the subsequent assessments took place, we still
observed significant changes in cytokine production over time
(data not shown). In addition, the changes in cytokine production
over time were not caused by differences in the duration of sample
storage in the freezer, since the participants were included in
cohorts and therefore the samples from the first assessments have
not all been stored longer than samples from the second and third
assessments. In addition, if the changes had resulted from
degradation of samples then we would have expected that the
changes over time were all in the same direction.
It was previously reported that severely stressed individuals [56],
including deployed military personnel [57,58], are at increased risk
for later development of medical conditions. It may well be that
the observed decreased innate cytokine production after deploy-
ment is involved in this increased risk for development of medical
conditions, such as bacterial infections. In addition, if the increased
capacity of T-cells to produce cytokines lasts for a long period or
becomes a stable feature, it may contribute to development of
inflammatory conditions, such as atherosclerosis [59,60].
The observed change in cytokine and chemokine production
was long-lasting: 6 months after return the effect was still present.
Future studies should investigate how long after return from
deployment the observed changes in cytokine production last. This
is important since we observed that high T-cell cytokine
production is a risk factor for development of depressive
symptoms. If a new stressor would occur when the observed T-
cell cytokine production has not yet decreased, it may well be
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development of depressive symptomatology in response to this new
stressor. Indeed, there is evidence that soldiers who have been
deployed previously are at increased risk for development of
combat-related MDD [61]. However, not all studies have found
an association between previous deployment and development of
depression in response to a new deployment [62]. One possible
confounding factor could be that the interval between deploy-
ments differs between studies and between participants within the
studies. In future studies, it would be interesting to take the interval
between the deployments into account while investigating this
relationship.
In addition to the observed pre-existing difference in T-cell
cytokine production, individuals with depressive symptoms after
deployment also responded differently to the deployment: the
group with depressive symptoms after deployment showed a
smaller increase in mitogen-induced T-cell cytokine production in
response to deployment than the non-depressed group. This
observed group difference in the trajectory of T-cell cytokine
production over time could not be attributed to a difference in the
number of experienced deployment stressors. However, we cannot
exclude that potential differences in the experienced subjective
severity of these stressors did affect the trajectory of T-cell cytokine
production.
The development of depressive symptoms was not associated
with the change in T-cell-induced chemokine/IL-6 production
and innate cytokine production over time. In addition, innate
cytokine production and chemokine production before deploy-
ment were also unrelated to development of depressive symptoms
In individuals who already had developed MDD or depressive
symptoms, increases in innate cytokine production have repeatedly
been reported [2–6]. Based on our findings we hypothesize that an
increase in mitogen-induced production of innate cytokines may
develop only as a consequence of the presence of depressive
symptomatology and does not represent a vulnerability factor for
development of depressive symptoms.
A limitation of the current study is that depressive symptoms
were assessed with self-report questionnaires, and that official
MDD diagnoses could therefore not be made. However, the
validity of the used SCL-90 depression subscale has repeatedly
been investigated and the questionnaire has been found to be a
valid and reliable screening tool for the presence of MDD [25–27].
Another limitation is that we did not include a non-deployed
control group. We interpret the observed changes in mitogen-
induced cytokine production over time as consequences of the
severe stress experienced during the deployment, but we cannot
exclude that other factors contribute to the observed changes in
mitogen-induced cytokine production.
The current study is the first to show that the capacity of
monocytes and T-cells to produce cytokines and chemokines was
altered after exposure to severe stress, i.e. deployment to a combat-
zone, until at least 6 months after return. In addition, we found
that pre-existing high mitogen-induced T-cell cytokine production
is a predictor for the development of depressive symptoms in
response to military deployment. We propose that high mitogen-
induced T-cell cytokine production may be a vulnerability factor
for increased risk for development of depressive symptomatology
after exposure to a period of severe stress, such as experienced
during military deployment.
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